EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Stephanie Meier, Eline A J Willemse, Sabine Schaedelin, Johanna Oechtering, Johannes Lorscheider, Lester Melie-Garcia, Alessandro Cagol, Muhamed Barakovic, Riccardo Galbusera, Suvitha Subramaniam, Christian Barro, Ahmed Abdelhak und 29 weitere

JAMA Neurology · 01.03.2023 · 80 (3) · 287

DOI: 10.1001/jamaneurol.2022.5250 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Neurology, erschienen am 01.03.2023. Verfasst von Stephanie Meier und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital and University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 287-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance There is a lack of validated biomarkers for disability progression independent of relapse activity (PIRA) in multiple sclerosis (MS).

Objective

To determine how serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) correlate with features of disease progression vs acute focal inflammation in MS and how they can prognosticate disease progression. Design, Setting, and Participants Data were acquired in the longitudinal Swiss MS cohort (SMSC; a consortium of tertiary referral hospitals) from January 1, 2012, to October 20, 2022. The SMSC is a prospective, multicenter study performed in 8 centers in Switzerland. For this nested study, participants had to meet the following inclusion criteria: cohort 1, patients with MS and either stable or worsening disability and similar baseline Expanded Disability Status Scale scores with no relapses during the entire follow-up; and cohort 2, all SMSC study patients who had initiated and continued B-cell–depleting treatment (ie, ocrelizumab or rituximab). Exposures Patients received standard immunotherapies or were untreated. Main Outcomes and Measures In cohort 1, sGFAP and sNfL levels were measured longitudinally using Simoa assays. Healthy control samples served as the reference. In cohort 2, sGFAP and sNfL levels were determined cross-sectionally.

Results

This study included a total of 355 patients (103 [29.0%] in cohort 1: median [IQR] age, 42.1 [33.2-47.6] years; 73 female patients [70.9%]; and 252 [71.0%] in cohort 2: median [IQR] age, 44.3 [33.3-54.7] years; 156 female patients [61.9%]) and 259 healthy controls with a median [IQR] age of 44.3 [36.3-52.3] years and 177 female individuals (68.3%). sGFAP levels in controls increased as a function of age (1.5% per year; P < .001), were inversely correlated with BMI (−1.1% per BMI unit; P = .01), and were 14.9% higher in women than in men ( P = .004). In cohort 1, patients with worsening progressive MS showed 50.9% higher sGFAP levels compared with those with stable MS after additional sNfL adjustment, whereas the 25% increase of sNfL disappeared after additional sGFAP adjustment. Higher sGFAP at baseline was associated with accelerated gray matter brain volume loss (per doubling: 0.24% per year; P < .001) but not white matter loss. sGFAP levels remained unchanged during disease exacerbations vs remission phases. In cohort 2, median (IQR) sGFAP z scores were higher in patients developing future confirmed disability worsening compared with those with stable disability (1.94 [0.36-2.23] vs 0.71 [−0.13 to 1.73]; P = .002); this was not significant for sNfL. However, the combined elevation of z scores of both biomarkers resulted in a 4- to 5-fold increased risk of confirmed disability worsening (hazard ratio [HR], 4.09; 95% CI, 2.04-8.18; P < .001) and PIRA (HR, 4.71; 95% CI, 2.05-9.77; P < .001). Conclusions and Relevance Results of this cohort study suggest that sGFAP is a prognostic biomarker for future PIRA and revealed its complementary potential next to sNfL. sGFAP may serve as a useful biomarker for disease progression in MS in individual patient management and drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMaleHumansFemaleAdultMiddle AgedCohort StudiesGlial Fibrillary Acidic ProteinIntermediate FilamentsProspective StudiesDisease ProgressionBiomarkersNeurofilament ProteinsRecurrence

Substanzen

Glial Fibrillary Acidic ProteinBiomarkersNeurofilament Proteins

Autor:innen und Institutionen

  • Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.
  • Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
  • Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Switzerland.
  • Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Translational Imaging in Neurology Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Department of Neurology, Harvard Medical School, Boston, Massachusetts.

Zitieren

APA

Meier, S., Willemse, E. A. J., Schaedelin, S., Oechtering, J., Lorscheider, J., Melie-Garcia, L., Cagol, A., Barakovic, M., Galbusera, R., Subramaniam, S., Barro, C., Abdelhak, A., Thebault, S., Achtnichts, L., Lalive, P., Müller, S., Pot, C., Salmen, A., Disanto, G., …, & Kuhle, J. (2023). Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurology, 80(3), 287. https://doi.org/10.1001/jamaneurol.2022.5250

Vancouver

Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, et al. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurology. 2023;80(3):287. doi:10.1001/jamaneurol.2022.5250

BibTeX
@article{Meier2023,
  author = {Meier, Stephanie and Willemse, Eline A J and Schaedelin, Sabine and Oechtering, Johanna and Lorscheider, Johannes and Melie-Garcia, Lester and Cagol, Alessandro and Barakovic, Muhamed and Galbusera, Riccardo and Subramaniam, Suvitha and Barro, Christian and Abdelhak, Ahmed and Thebault, Simon and Achtnichts, Lutz and Lalive, Patrice and Müller, Stefanie and Pot, Caroline and Salmen, Anke and Disanto, Giulio and Zecca, Chiara and D'Souza, Marcus and Orleth, Annette and Khalil, Michael and Buchmann, Arabella and Du Pasquier, Renaud and Yaldizli, Özgür and Derfuss, Tobias and Berger, Klaus and Hermesdorf, Marco and Wiendl, Heinz and Piehl, Fredrik and Battaglini, Marco and Fischer, Urs and Kappos, Ludwig and Gobbi, Claudio and Granziera, Cristina and Bridel, Claire and Leppert, David and Maleska Maceski, Aleksandra and Benkert, Pascal and Kuhle, Jens},
  title = {Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis},
  journal = {JAMA Neurology},
  year = {2023},
  volume = {80},
  number = {3},
  pages = {287},
  doi = {10.1001/jamaneurol.2022.5250}
}
Kostenlos starten →